Thyroid hormone action in the heart

GJ Kahaly, WH Dillmann - Endocrine reviews, 2005 - academic.oup.com
The heart is a major target organ for thyroid hormone action, and marked changes occur in
cardiac function in patients with hypo-or hyperthyroidism. T3-induced changes in cardiac …

Cardiovascular and atherogenic aspects of subclinical hypothyroidism

GJ Kahaly - Thyroid, 2000 - liebertpub.com
Subclinical hypothyroidism (SH) is common, especially among elderly women. There is no
clear evidence to date that SH causes clinical heart disease. However, mild thyroid gland …

Thyroid dysfunction and diabetes mellitus: two closely associated disorders

B Biondi, GJ Kahaly, RP Robertson - Endocrine reviews, 2019 - academic.oup.com
Thyroid dysfunction and diabetes mellitus are closely linked. Several studies have
documented the increased prevalence of thyroid disorders in patients with diabetes mellitus …

Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO

L Bartalena, L Baldeschi, A Dickinson… - European Journal of …, 2008 - academic.oup.com
Methods European Group on GO (EUGOGO) represents a multidisciplinary consortium of
clinicians from the European centers, who share a commitment to improving the …

The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy

L Bartalena, GJ Kahaly, L Baldeschi… - European journal of …, 2021 - academic.oup.com
Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease (GD).
Choice of treatment should be based on the assessment of clinical activity and severity of …

[HTML][HTML] Teprotumumab for thyroid-associated ophthalmopathy

TJ Smith, GJ Kahaly, DG Ezra… - … England Journal of …, 2017 - Mass Medical Soc
Background Thyroid-associated ophthalmopathy, a condition commonly associated with
Graves' disease, remains inadequately treated. Current medical therapies, which primarily …

[HTML][HTML] The 2016 European Thyroid Association/European Group on Graves' orbitopathy guidelines for the management of Graves' orbitopathy

L Bartalena, L Baldeschi, K Boboridis… - European thyroid …, 2016 - etj.bioscientifica.com
Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease, though
severe forms are rare. Management of GO is often suboptimal, largely because available …

Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy

L Bartalena, L Baldeschi, AJ Dickinson, A Eckstein… - Thyroid, 2008 - liebertpub.com
Graves' orbitopathy (GO) constitutes a major clinical and therapeutic challenge (1, 2). GO is
an autoimmune disorder representing the commonest and most important extrathyroidal …

[HTML][HTML] Selenium and the course of mild Graves' orbitopathy

C Marcocci, GJ Kahaly, GE Krassas… - … England Journal of …, 2011 - Mass Medical Soc
Background Oxygen free radicals and cytokines play a pathogenic role in Graves'
orbitopathy. Methods We carried out a randomized, double-blind, placebo-controlled trial to …

Randomized, Single Blind Trial of Intravenous versus Oral Steroid Monotherapy in Graves' Orbitopathy

GJ Kahaly, S Pitz, G Hommel… - The Journal of Clinical …, 2005 - academic.oup.com
Context: Glucocorticoids are effective for severe Graves' orbitopathy (GO), which causes
substantial morbidity. The question at issue is how best to use them. Objective: The objective …